Standard Medicare Part B Management Imdelltra
Customize your policy alerts
Sign up for clover_health Policy 6501-A alerts
Get alerted when Policy 6501-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs Medicare Part B coverage and authorization for Imdelltra (tarlatamab-dlle), including FDA-approved and compendial uses, for Clover Health members. It primarily covers extensive-stage small cell lung cancer after progression on or after platinum-based chemotherapy and sets initial and continuation authorization criteria.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.